Literature DB >> 15181369

Glucosylceramide synthase activity and ceramide levels are modulated during cerebral ischemia after ischemic preconditioning.

Kenzo Takahashi1, Irene Ginis, Ryoji Nishioka, Dace Klimanis, Frank C Barone, Raymond F White, Yong Chen, John M Hallenbeck.   

Abstract

After 24-hour middle cerebral artery occlusion (MCAO) in spontaneously hypertensive rats, brain ceramide level increased from baseline reached 595% (ischemic core) and 460% (perifocal/penumbral areas); brain glucosylceramide synthase (GCS) activities in these areas simultaneously decreased by 70% and 50%, respectively. Ten-minute MCAO preconditioning significantly attenuated 24-hour MCAO-induced ceramide accumulation by 40% to 60% in ischemic core and perifocal areas, and GCS activities improved by 60% to 70% in both areas. Thus, potentially toxic levels of brain ceramide induced by MCAO were attenuated to intermediate levels in preconditioned animals; brain GCS activity was relatively preserved. In ischemic tolerance, GCS appears to modulate otherwise high levels of brain ceramide.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15181369     DOI: 10.1097/01.WCB.0000119990.06999.A9

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  12 in total

1.  Ceramide and mitochondria in ischemic brain injury.

Authors:  Sergei A Novgorodov; Tatyana I Gudz
Journal:  Int J Biochem Mol Biol       Date:  2011-11-25

Review 2.  The roles of neutral sphingomyelinases in neurological pathologies.

Authors:  Charles R Horres; Yusuf A Hannun
Journal:  Neurochem Res       Date:  2012-01-12       Impact factor: 3.996

3.  Changes in the metabolism of sphingolipids after subarachnoid hemorrhage.

Authors:  Fernando D Testai; Hao-Liang Xu; John Kilkus; Vidyani Suryadevara; Irina Gorshkova; Evgeny Berdyshev; Dale A Pelligrino; Glyn Dawson
Journal:  J Neurosci Res       Date:  2015-01-19       Impact factor: 4.164

Review 4.  Ceramide and neurodegeneration: susceptibility of neurons and oligodendrocytes to cell damage and death.

Authors:  Arundhati Jana; Edward L Hogan; Kalipada Pahan
Journal:  J Neurol Sci       Date:  2009-01-14       Impact factor: 3.181

Review 5.  Ceramide and mitochondria in ischemia/reperfusion.

Authors:  Sergei A Novgorodov; Tatyana I Gudz
Journal:  J Cardiovasc Pharmacol       Date:  2009-03       Impact factor: 3.105

6.  Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer's disease: a shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer's disease?

Authors:  Pavel Katsel; Celeste Li; Vahram Haroutunian
Journal:  Neurochem Res       Date:  2007-03-07       Impact factor: 3.996

Review 7.  Sphingolipids in cardiovascular diseases and metabolic disorders.

Authors:  Sonia Borodzicz; Katarzyna Czarzasta; Marek Kuch; Agnieszka Cudnoch-Jedrzejewska
Journal:  Lipids Health Dis       Date:  2015-06-16       Impact factor: 3.876

8.  Suppression of Acid Sphingomyelinase Protects the Retina from Ischemic Injury.

Authors:  Jie Fan; Bill X Wu; Craig E Crosson
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-08-01       Impact factor: 4.799

Review 9.  Ceramide and Ischemia/Reperfusion Injury.

Authors:  Xingxuan He; Edward H Schuchman
Journal:  J Lipids       Date:  2018-01-21

10.  Homozygous Smpd1 deficiency aggravates brain ischemia/ reperfusion injury by mechanisms involving polymorphonuclear neutrophils, whereas heterozygous Smpd1 deficiency protects against mild focal cerebral ischemia.

Authors:  Nina Hagemann; Ayan Mohamud Yusuf; Carlotta Martiny; Xiaoni Zhang; Christoph Kleinschnitz; Matthias Gunzer; Richard Kolesnick; Erich Gulbins; Dirk M Hermann
Journal:  Basic Res Cardiol       Date:  2020-10-14       Impact factor: 17.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.